Literature DB >> 2379134

Neurite outgrowth and cell cycle kinetic changes induced by cis-diamminedichloroplatinum II and retinoic acid in a human neuroblastoma cell line.

D Di Martino1, C Avignolo, B Marsano, A Di Vinci, A Cara, W Giaretti, G P Tonini.   

Abstract

The aim of this study was to analyze by flow cytometry the effect of cis-diamminedichloroplatinum II (CDDP) and retinoic acid (RA) on the cell cycle of a neuroblastoma cell line (SK-N-BE (2)C NB) and to correlate the kinetic data with cell morphology. CDDP at 1 microgram/ml induced a dramatic G2 + M cell cycle phases block (nearly 200% increase with respect to control) 2 days after treatment. The G2 + M block was spontaneously reversed starting from the 4th day. The cells treated with 10 microM RA were, instead, induced to irreversibly enter the G0 + G1 phase of the cell cycle (nearly 20% increase with respect to control) 48 h after treatment. Neurite-like structures were observed for both CDDP and RA treated cells. These data suggest different cell cycle dependent molecular mechanisms and different degrees of differentiation during CDDP or RA treatment of NB cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379134     DOI: 10.1016/0304-3835(90)90251-r

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  Novel retinoic acid derivative induces differentiation and growth arrest in neuroblastoma.

Authors:  Raoud Marayati; Adele P Williams; Laura V Bownes; Colin H Quinn; Jerry E Stewart; Elizabeth Mroczek-Musulman; Venkatram R Atigadda; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2020-02-28       Impact factor: 2.545

3.  Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2015-05-05       Impact factor: 6.261

4.  UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.

Authors:  Evan F Garner; Laura L Stafman; Adele P Williams; Jamie M Aye; Caroline Goolsby; Venkatram R Atigadda; Blake P Moore; Li Nan; Jerry E Stewart; Anita B Hjelmeland; Gregory K Friedman; Elizabeth A Beierle
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.